Posted by Michael Wonder on 27 Sep 2022
PHARMAC seeking feedback on nusinersen sodium and adrenaline auto-injectors funding
28 September 2022 - PHARMAC has initiated two consultations today, seeking feedback on the funding of two different medicines that we've heard are very important to many New Zealanders.
One is for funding nusinersen sodium (Spinraza) for people with the rare genetic disorder spinal muscular atrophy, and the other is for funding adrenaline auto-injectors for people at risk of anaphylaxis.
